There are currently 65 active clinical trials seeking participants for Cystic Fibrosis research studies. The states with the highest number of trials for Cystic Fibrosis participants are Ohio, California, New York and Florida.
Regional Phenotyping of CF and Non-CF Bronchiectasis
Recruiting
The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.
Gender:
ALL
Ages:
Between 5 years and 100 years
Trial Updated:
02/18/2025
Locations: Penny New, Cincinnati, Ohio
Conditions: Cystic Fibrosis, Non-CF Bronchiectasis
Hormonal Responses to a Mixed Meal in People with Cystic Fibrosis
Recruiting
In this exploratory study, the hormonal responses to a mixed meal will be examined in people with cystic fibrosis. The aim of this study is to find correlates with impaired glucose tolerance that is associated with this population.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/08/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Cystic Fibrosis
Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials
Recruiting
The purpose of this study is to validate and utilize a personalized medicine approach to identify potential treatments with current FDA approved CFTR modifiers for non-approved CF gene mutations. The study will perform ex vivo testing of CFTR function and current marketed CFTR modulating drugs on expanded nasal cells at Cincinnati Children's Human Nasal Epithelium (HNE) Core Laboratory. The results will be confirmed and translated into bedside care through an N of 1 trial to determine effectiven... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
09/18/2024
Locations: CCHMC, Cincinnati, Ohio
Conditions: Cystic Fibrosis
Regional Monitoring of CF Lung Disease
Recruiting
The main reason for this research study is to learn more about some new tests that are being developing for patients with Cystic Fibrosis (CF) to measure changes in the lungs. In this study, the focus will be to learn how stopping Airway Clearance (ACT) and re-starting ACT can affect these tests. These new tests include using a breathable gas called Xenon (Xe) with MRI (magnetic resonance imaging) to improve the pictures of changes in the lungs. The Xenon (Xe) gas that has been treated to have a... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
03/29/2024
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Cystic Fibrosis
Natural History of Bronchiectasis
Recruiting
Background: * Bronchiectasis is a disease characterized by airways that are inflamed, abnormally dilated, and chronically infected. Individuals with bronchiectasis have a history of chronic and recurring respiratory infections. Depending on the underlying cause, these infections may involve the entire respiratory tract, resulting in sinus, ear, and lung disease. * Bronchiectasis continues to be a significant problem in developing countries and in specific groups of individuals, particularly in... Read More
Gender:
ALL
Ages:
Between 5 years and 100 years
Trial Updated:
05/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Bronchiectasis, Cystic Fibrosis, Autoimmune Disease, Common Variable Immunodeficiency
Role of Genetic Factors in the Development of Lung Disease
Recruiting
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers. Optional CT Sub-study The standard CT scan will be compared to the low dose radiation CT s... Read More
Gender:
ALL
Ages:
Between 2 years and 90 years
Trial Updated:
05/09/2025
Locations: Suburban Hospital, Bethesda, Maryland +1 locations
Conditions: Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma, Pulmonary Sarcoidosis
A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF
Recruiting
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/07/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +22 locations
Conditions: Cystic Fibrosis
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
Recruiting
The purpose of this study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Gender:
ALL
Ages:
Between 1 year and 11 years
Trial Updated:
05/06/2025
Locations: Children's Hospital of Orange County, Orange, California +34 locations
Conditions: Cystic Fibrosis
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
Recruiting
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient pulmonary exacerbations (PEx) in the pediatric CF population.
Gender:
ALL
Ages:
Between 3 years and 18 years
Trial Updated:
05/01/2025
Locations: The Children's Hospital Alabama & University of Alabama at Birmingham, Birmingham, Alabama +32 locations
Conditions: Cystic Fibrosis
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
Recruiting
The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/29/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Cystic Fibrosis
Diagnosis and Treatment of Patients With Cystic Fibrosis
Recruiting
This is an omnibus protocol for studying patients with cystic fibrosis. The main purpose of the study is to obtain samples and data collected during standard clinical care for future research to expand knowledge of the natural history, clinical manifestations (phenotypes) and the genetic variants (genotypes) of cystic fibrosis.
Gender:
ALL
Ages:
Between 4 years and 120 years
Trial Updated:
04/29/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
Remote Sputum Collection in Cystic Fibrosis
Recruiting
Elexacaftor/Tezacaftor/Ivacaftor or Trikafta improves lung health in people with cystic fibrosis (CF), including decreased cough and mucous production. Diagnosing lung infections has become more challenging due to the decrease in sputum and rise of telehealth services. While the option of collecting sputum samples at home and sending them by mail may be feasible, uncertainty remains about how the collection of samples outside of clinic and delays in testing while in the mail impact infection det... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: National Jewish Health, Denver, Colorado +2 locations
Conditions: Cystic Fibrosis, Infections